[0013] In a further aspect, this disclosure features regimens for treating depression in a human patient, which include delivering to the patient GLYX-13 in a cycle of treatment, said cycle comprising intravenously administering a dosage of about 5 mg/kg to about 10 mg/kg of GLYX-13 (or about 2.5 mg/kg to about 10 mg/kg of GLYX-13, or for example, about 225mg to about 900 mg of GLYX-13) per week or every other week for at least four weeks in the cycle followed by at least one week, two weeks, three weeks, four weeks, two months or more where no GLYX-13 is administered.

[0013a] In another aspect, this disclosure features use of a composition comprising GLYX-13 in the manufacture of a medicament for stabilizing a patient being treating for depression, wherein the medicament is to be intravenously administered to the patient once every week or once every two weeks for an induction period of time.

[0013b] In another aspect, this disclosure features use of between about 2.5mg/kg and about 10mg/kg of GLYX-13 in the manufacture of a medicament for treating depression in a patient need thereof, wherein the medicament is to be sequentially administered to the patient for a first period of time, and wherein the sequential administration is followed by non-administration of GLYX-13 for a rest period of time of time.

[0013c] In another aspect, this disclosure features use of GLYX-13 in the manufacture of a medicament for treating depression in a human patient, wherein the medicament is to be delivered to the patient in a cycle of treatment, wherein said cycle comprises a dosage of about 225mg to about 900 mg of medicament to be intravenously administered per week or every other week for at least four weeks in the cycle followed by at least one week, two weeks, three weeks, four weeks, two months or more where no GLYX-13 is to be administered.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] **FIG. 1** is a graph showing improvements (based on HDRS scale) achieved during an induction period of time (identified as "stabilization" on the graph) are generally maintained throughout the rest period of time (identified as "randomized withdrawal" on the graph), although HDRS scores did vary with dosage frequency.

What is claimed is:

1. Use of a composition comprising GLYX-13 in the manufacture of a medicament for stabilizing a patient being treating for depression, wherein the medicament is to be intravenously administered to the patient once every week or once every two weeks for an induction period of time.

2. The use of claim 1, wherein the patient being treated for depression is being administered another anti-depressant without achieving a full response to treatment on the other anti-depressant alone.

3. The use of claim 1 or 2, wherein the induction period of time is about five weeks to about eight weeks, or about three weeks to about twelve weeks or more.

4. The use of any one of claims 1-3, wherein the induction period of time is about six weeks.

5. The use of any one of claims 1-4, wherein the after the induction period of time, the medicament is not administered to the patient for a rest period of time of time.

6. The use of any one of claims 2-5, wherein the patient is to be administered the other anti-depressant during the rest period of time.

7. The use of claim 1-6, wherein the induction period of time is three weeks, four weeks, five weeks, two months, or more.

8. The use of any one of claims 5-7, wherein during the rest period of time of time, the patient substantially maintains the improvement of depression symptoms as compared to the improvement after the induction period of time as indicated by the HDRS-17 scale.

9. The use of claim 8, wherein during the rest period of time of time, the patient substantially maintains the improvement of depression symptoms by administration of the other antidepressant as compared to the improvement after the induction period of time as indicated by the HDRS-17 scale.

10. The use of any one of claims 5-9, wherein during the rest period of time of time, the patient has a HDRS-17 score of less than or about 7.

11. The use of claim 5-7, wherein during the rest period of time of time, the patient substantially maintains the improvement of depression symptoms as compared to the improvement after the induction period of time as indicated by the MADRS scale.

12. The use of claim 11, wherein during the rest period of time of time, the patient has a MADRS score of less than or about 10.

13. The use of any one of claims 7-12, wherein immediately after the induction period and during the rest period of time of time, the patient maintains a less than or equal to about 50% reduction in depression symptoms.

14. The use of claim 1, wherein the patient is also being administered another anti-depressant agent before, during or after the induction period.

15. Use of between about 2.5mg/kg and about 10mg/kg of GLYX-13 in the manufacture of a medicament for treating depression in a patient in need thereof, wherein the medicament is to be sequentially administered to the patient for a first period of time, and wherein the sequential administration is followed by non-administration of GLYX-13 for a rest period of time.

16. The use of claim 15, wherein the sequential administration and non-administration are repeated at least once.

17. The use of claim 15 or 16, wherein the medicament is to be administered weekly or every other week for a first period of time of about three weeks to about twelve weeks, and wherein the rest period of time is about one to about six weeks or more.

18. The use of any one of claims 15-17, wherein the medicament comprises about 5 mg/kg or about 10 mg/kg of GLYX-13, and wherein the medicament is to be administered weekly or every other week for six to twelve weeks.

19. The use of any one of claims 15-18, wherein the patient is also being administered another antidepressant agent before and/or during or after the first period of time.

20. The use of any one of claims 15-19, wherein the patient is being administered another antidepressant agent during the rest period of time of time.

21. Use of GLYX-13 in the manufacture of a medicament for treating depression in a human patient, wherein the medicament is to be delivered to the patient in a cycle of treatment, wherein said cycle comprises a dosage of about 225mg to about 900 mg of medicament to be intravenously administered per week or every other
week for at least four weeks in the cycle followed by at least one week, two weeks, three weeks, four weeks, two months or more where no GLYX-13 is to be administered.

22. The use according to claim 16, wherein the cycle comprises at least three weekly dosage administrations.

23. The use according to claim 19, wherein the cycle is to be repeated at least once.

24. The use according to any one of claims 21-23, wherein the cycle is to be repeated for two to twelve cycles.

25. The use according to any one of claims 21-24, wherein the cycles are continuous.

26. The use according to any one of claims 21-25, wherein the patient is also being administered another antidepressant agent before and/or during the cycle.

27. The use of any one of claims 1-26 wherein the depression is treatment-resistant depression.

28. The use of claim 27, wherein the treatment-resistant patient is identified as one who has been treated with at least one type of antidepressant treatments prior to administration of GLYX-13.

29. The use of claim 27, wherein the treatment-resistant patient is identified as one who has been treated with at least two types of antidepressant treatments prior to administration of GLYX-13.

30. The use of any one of claims 1-29, wherein said depression is selected from the group consisting of major depressive disorder, dysthymic disorder, psychotic depression, postpartum depression, seasonal affective disorder, bipolar disorder, bipolar depression, mood disorder, depressions caused by chronic medical conditions such as cancer or chronic pain, chemotherapy, chronic stress, post traumatic stress disorders, and manic depressive disorder.